How the Teal Health UC Davis pilot could reshape cervical cancer screening workflows
Teal Health and UC Davis Health test how FDA-authorized at-home HPV screening can fit routine care and reach overdue patients.
Medical Devices & Diagnostics
Pharma & Biotech
Mabwell’s Nectin-4 ADC shows cervical cancer activity, but can Phase 3 confirm survival benefit?
Updated 9MW2821 data support Nectin-4 as a target in cervical cancer, but Mabwell must prove that early response and survival signals outperform established ADC and immunotherapy options.
Pharma & Biotech
Can Kovina Therapeutics turn HPV16 E6 from an undruggable viral protein into a cancer target?
See how Kovina Therapeutics’ HPV16 E6 inhibitors restore p53 in preclinical models and what must happen before human trials.
Pharma & Biotech
TIVDAK approval gives Zai Lab a sharper China oncology story, but execution risk remains
TIVDAK enters China’s cervical cancer market with survival data. See why Zai Lab’s ADC approval matters beyond oncology headlines.
Medical Devices & Diagnostics
Agilent wins FDA backing to move more Keytruda-linked PD-L1 testing onto Dako Omnis
Find out how Agilent’s expanded PD-L1 test approval could change automated cancer diagnostics and oncology lab workflows.
Pharma & Biotech
Avacta’s pre|CISION exatecan conjugate reaches Phase 1 as competition in targeted topo I inhibitors intensifies
Avacta opens Phase 1 trial of FAP-Exd (AVA6103) in four advanced solid tumors. Analysis of what the sustained-release exatecan conjugate must prove in 2026.